Although TERT promoter mutation and EGFR amplification may be common canonical alterations for IDH-wildtype GBM that may guide diagnosis and define mGBM, they do not appear prognostic for established IDH-wildtype GBM cases. The gene discussed is IDH2; the disease is glioblastoma.